Category: Deals
-
Sensei Bio stock skyrockets on acquisition and $200m financing
Sensei stock surges after acquiring Faeth Therapeutics and securing $200 million private placement to advance cancer pipeline.
-
Evogene and Australian Uni partner to tackle chemotherapy resistance in lung cancer
AI-driven collaboration between the Israeli company and Queensland University of Technology targets cellular pathways to overcome treatment hurdles in non-small cell lung cancer.
-
Becton Dickinson and ten23 partner on wearable injector supply
Partnership will support the supply for Becton, Dickinson and Company’s self-administered therapies with a ready-to-use, scalable platform.
-
Iolyx and Théa partner on $280 million autoimmune eye drug deal
Concurrently with the collaboration deal for ILYX-002 for autoimmune-associated dry eye disease, Iolyx announced a $15 million Series B financing.
-
Regeneron and Tessera ink $275 mil pact for gene editing therapy
The companies will co-develop TSRA-196, a potential one-time genetic treatment for alpha-1 antitrypsin deficiency.
-
Santersus secures funding to advance blood purification tech
Swiss biotech raises Series A financing to drive pivotal trials for its blood purification technology for sepsis and lupus therapy.
-
Saliva pregnancy test hits Australian shelves
Salignostics partners with Coles Supply to launch its innovative SaliStick saliva-based pregnancy test across Australia.
-
New Swiss alliance to improve cell therapy manufacturing
The industry-academia partnership of Bracco Imaging, Limula, and the University of Fribourg aims to revolutionize how life-saving ‘living drugs’ are made.
-
Adagene & Third Arc Bio forge $845 million T-cell engager pact
Adagene licenses its SAFEbody tech to Third Arc Bio for two masked CD3 T cell engagers, netting $5million upfront, and upto $840 million in milestone payments.
-
Chiesi licenses AbbVie unit’s brain-targeting tech for rare diseases
The partnership with Aliada Therapeutics centers on a platform technology designed to ferry large-molecule therapies across the protective blood-brain barrier (BBB) for lysosomal storage disorders (LSDs).
-
ten23 health and Neumirna partner to advance RNA therapy for epilepsy
The collaboration seeks to advance NMT.001, an RNA-based therapy targeting microRNAs involved in drug-resistant epilepsy.
-
Cidara secures $339m from BARDA for non-vaccine flu therapy
Cidara Therapeutics wins BARDA backing to expand US manufacturing and clinical development of its long-acting, non-vaccine influenza therapeutic, CD388.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.